Clot regression effects of rivaroxaban in treatment of venous thromboembolism in cancer patients. - Clot regression effects of rivaroxaban in treatment of venous thromboembolism in cancer patients.

Kyoto Prefectural University of Medicine0 个研究点目标入组 40 人开始时间: 2017年6月17日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方: Kyoto Prefectural University of Medicine
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

This study revealed that rivaroxaban had a sufficient clot-regression effect for the treatment of VTE in cancer patients. It exhibited an acceptable safety profile; however, future clinical use in patients with gastrointestinal or genitourinary cancers should be met with caution.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 75years-old（—）
性别: All

入选标准

未提供

排除标准

•Patients contraindicated for rivaroxaban, with creatinine clearance <30 mL/min, with isolated distal DVT, within 6 months in the remaining days, with a vitamin K antagonist, with severe complication (significant liver disease, active bleeding or a high risk of bleeding contraindicating anticoagulant treatment, severe hypertension (a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg)), pregnancy, and breast-feeding. Patients who the physician in charge judges are ineligible for the present study.

研究者

发起方

Kyoto Prefectural University of Medicine

相似试验

已完成

4 期

Clot regression effects of rivaroxaban in treatment of venous thromboembolism in cancer patients.Venous thromboembolism

JPRN-jRCTs051180077Matoba Satoaki40

已完成

2 期

Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee ArthroscopyHaemorrhageVenous Thromboembolism

NCT01629381University of Padova500

已完成

不适用

An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)Treatment of Venous Thromboembolism in Cancer PatientsCancerVenous Thromboembolism

NCT05461807Bayer2,437

已完成

不适用

A Prospective Pharmacodynamic Study of RivaroxabanBlood Clot

NCT01743898University of North Carolina, Chapel Hill65

已完成

3 期

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill PatientsVenous Thromboembolism

NCT00571649Bayer8,101